Clinical and laboratory findings of patients with VITT as a result of vaccination with Ad26.COV2.S (Johnson & Johnson/Janssen) compared with patients with VITT who were vaccinated with ChAdOx1 nCoV-19 (AstraZeneca)
| . | Patient 1 . | Patient 2 . | Patient 3 . | VITT∗ (n = 5) . |
|---|---|---|---|---|
| Age mean (range) | 28 | 39 | 61 | 44 (35-72) |
| Sex | F | F | F | 3M/2F |
| Platelet count × 109/L | 71 | 36 | 19 | — |
| Thrombosis | Y | Y | Y | Y |
| Site of thrombosis | Right internal jugular vein, right transverse, cerebral venous, and superior sagittal sinuses | Cerebral venous sinus | Portal vein | — |
| Anti-PF4 ELISA (OD405 nm >0.4) mean (range) | 2.41 | 1.21 | 2.75 | 2.71 (0.76-3.35) |
| Standard SRA (14C-serotonin ≥20%) | Positive | — | Positive | Negative 0/5 |
| PF4 SRA or PEA (14C-serotonin ≥20%) | Positive | Positive | Positive | Positive (5/5) |
| No. of amino acids in VITT binding site (n/8) | 8/8 | 5/8 | 6/8 | 4/8 (mean) |
| Binding response to PF4, nm (mean ± SD [range]) | 2.30 | 0.64 | 3.81 | 1.82 ± 0.88 (0.60-3.07) |
| Binding response to PF4/heparin, nm (mean ± SD [range]) | 1.93 | 0.62 | 2.97 | 1.24 ± 0.70 (0.43-2.18) |
| . | Patient 1 . | Patient 2 . | Patient 3 . | VITT∗ (n = 5) . |
|---|---|---|---|---|
| Age mean (range) | 28 | 39 | 61 | 44 (35-72) |
| Sex | F | F | F | 3M/2F |
| Platelet count × 109/L | 71 | 36 | 19 | — |
| Thrombosis | Y | Y | Y | Y |
| Site of thrombosis | Right internal jugular vein, right transverse, cerebral venous, and superior sagittal sinuses | Cerebral venous sinus | Portal vein | — |
| Anti-PF4 ELISA (OD405 nm >0.4) mean (range) | 2.41 | 1.21 | 2.75 | 2.71 (0.76-3.35) |
| Standard SRA (14C-serotonin ≥20%) | Positive | — | Positive | Negative 0/5 |
| PF4 SRA or PEA (14C-serotonin ≥20%) | Positive | Positive | Positive | Positive (5/5) |
| No. of amino acids in VITT binding site (n/8) | 8/8 | 5/8 | 6/8 | 4/8 (mean) |
| Binding response to PF4, nm (mean ± SD [range]) | 2.30 | 0.64 | 3.81 | 1.82 ± 0.88 (0.60-3.07) |
| Binding response to PF4/heparin, nm (mean ± SD [range]) | 1.93 | 0.62 | 2.97 | 1.24 ± 0.70 (0.43-2.18) |
None of the 3 patients received heparin therapy before onset of symptoms.
ELISA, enzyme-linked immunosorbent assay; F, female; M, male; OD, optical density; SD, standard deviation; Y, yes.
Data from Huynh et al.5